These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 36320041)

  • 41. Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells.
    Chen MC; Lee CF; Huang WH; Chou TC
    Biochem Pharmacol; 2013 May; 85(9):1278-87. PubMed ID: 23416116
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hypoxic induction of HIF-1alpha and VEGF expression in head and neck squamous cell carcinoma lines is mediated by stress activated protein kinases.
    Shemirani B; Crowe DL
    Oral Oncol; 2002 Apr; 38(3):251-7. PubMed ID: 11978547
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of hypoxia and acidosis in promoting metastasis and resistance to chemotherapy.
    DeClerck K; Elble RC
    Front Biosci (Landmark Ed); 2010 Jan; 15(1):213-25. PubMed ID: 20036816
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Decursin promotes HIF-1α proteasomal degradation and immune responses in hypoxic tumour microenvironment.
    Ge Y; Yoon SH; Jang H; Jeong JH; Lee YM
    Phytomedicine; 2020 Nov; 78():153318. PubMed ID: 32896707
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting hypoxia and hypoxia-inducible factor-1 in the tumor microenvironment for optimal cancer immunotherapy.
    Kheshtchin N; Hadjati J
    J Cell Physiol; 2022 Feb; 237(2):1285-1298. PubMed ID: 34796969
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition of Ehrlich ascites cancer, hypoxia-inducible factor-1 alpha, and the kinase insert domain-containing receptor/
    Madhu LN; Telkar S; Kamath D; D Souza ME; Rao S; Nayak PS; Sarojini BK
    J Cancer Res Ther; 2020 Dec; 16(Supplement):S74-S81. PubMed ID: 33380656
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HIF expression and the role of hypoxic microenvironments within primary tumours as protective sites driving cancer stem cell renewal and metastatic progression.
    Philip B; Ito K; Moreno-Sánchez R; Ralph SJ
    Carcinogenesis; 2013 Aug; 34(8):1699-707. PubMed ID: 23740838
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Endothelial hypoxic metabolism in carcinogenesis and dissemination: HIF-A isoforms are a NO metastatic phenomenon.
    Branco-Price C; Evans CE; Johnson RS
    Oncotarget; 2013 Dec; 4(12):2567-76. PubMed ID: 24318195
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacologic stabilization of hypoxia-inducible transcription factors protects developing mouse brain from hypoxia-induced apoptotic cell death.
    Trollmann R; Richter M; Jung S; Walkinshaw G; Brackmann F
    Neuroscience; 2014 Oct; 278():327-42. PubMed ID: 25162122
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HIF-Dependent Mechanisms of Relationship between Hypoxia Tolerance and Tumor Development.
    Dzhalilova DS; Makarova OV
    Biochemistry (Mosc); 2021 Oct; 86(10):1163-1180. PubMed ID: 34903150
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Hypoxia and angiogenesis].
    Simon JM
    Bull Cancer; 2007 Jul; 94 Spec No():S160-5. PubMed ID: 17846000
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hypoxic stress simultaneously stimulates vascular endothelial growth factor via hypoxia-inducible factor-1α and inhibits stromal cell-derived factor-1 in human endometrial stromal cells.
    Tsuzuki T; Okada H; Cho H; Tsuji S; Nishigaki A; Yasuda K; Kanzaki H
    Hum Reprod; 2012 Feb; 27(2):523-30. PubMed ID: 22128293
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium.
    Pettersen EO; Ebbesen P; Gieling RG; Williams KJ; Dubois L; Lambin P; Ward C; Meehan J; Kunkler IH; Langdon SP; Ree AH; Flatmark K; Lyng H; Calzada MJ; Peso LD; Landazuri MO; Görlach A; Flamm H; Kieninger J; Urban G; Weltin A; Singleton DC; Haider S; Buffa FM; Harris AL; Scozzafava A; Supuran CT; Moser I; Jobst G; Busk M; Toustrup K; Overgaard J; Alsner J; Pouyssegur J; Chiche J; Mazure N; Marchiq I; Parks S; Ahmed A; Ashcroft M; Pastorekova S; Cao Y; Rouschop KM; Wouters BG; Koritzinsky M; Mujcic H; Cojocari D
    J Enzyme Inhib Med Chem; 2015; 30(5):689-721. PubMed ID: 25347767
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers.
    Bussink J; Kaanders JH; van der Kogel AJ
    Radiother Oncol; 2003 Apr; 67(1):3-15. PubMed ID: 12758235
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rhein inhibits angiogenesis and the viability of hormone-dependent and -independent cancer cells under normoxic or hypoxic conditions in vitro.
    Fernand VE; Losso JN; Truax RE; Villar EE; Bwambok DK; Fakayode SO; Lowry M; Warner IM
    Chem Biol Interact; 2011 Jul; 192(3):220-32. PubMed ID: 21457705
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Exploring hypoxic biology to improve radiotherapy outcomes.
    Li C; Wiseman L; Okoh E; Lind M; Roy R; Beavis AW; Pires IM
    Expert Rev Mol Med; 2022 Apr; 24():e21. PubMed ID: 35586915
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of the hypoxia-inducible factor in tumor metabolism growth and invasion.
    Brahimi-Horn C; Pouysségur J
    Bull Cancer; 2006 Aug; 93(8):E73-80. PubMed ID: 16935775
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetic and anti-cancer properties of high dose ascorbate in solid tumours of ascorbate-dependent mice.
    Campbell EJ; Vissers MCM; Wohlrab C; Hicks KO; Strother RM; Bozonet SM; Robinson BA; Dachs GU
    Free Radic Biol Med; 2016 Oct; 99():451-462. PubMed ID: 27567539
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fasudil-induced hypoxia-inducible factor-1alpha degradation disrupts a hypoxia-driven vascular endothelial growth factor autocrine mechanism in endothelial cells.
    Takata K; Morishige K; Takahashi T; Hashimoto K; Tsutsumi S; Yin L; Ohta T; Kawagoe J; Takahashi K; Kurachi H
    Mol Cancer Ther; 2008 Jun; 7(6):1551-61. PubMed ID: 18566226
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rhapontigenin inhibited hypoxia inducible factor 1 alpha accumulation and angiogenesis in hypoxic PC-3 prostate cancer cells.
    Jung DB; Lee HJ; Jeong SJ; Lee HJ; Lee EO; Kim YC; Ahn KS; Chen CY; Kim SH
    Biol Pharm Bull; 2011; 34(6):850-5. PubMed ID: 21628883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.